4th Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 2158 / H.R. 2507--Newborn Screening Saves Lives Reauthorization Act Executive Order 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States General issues related to orphan disease drugs; FDA modernization policy issues; Reauthorization of newborn screening programs; COVID-19 telemedicine flexibility; Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients; 304B drug discount program

LobbyistCovered position, as disclosed
KATIE JONES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2158 (116th), H.R. 2507 (116th)

Medicare/Medicaid MMM

H.R. 3--Elijah E. Cummings Lower Drug Costs Now Act H.R. 5741--The Strengthening Medicare and Medicaid Innovation Act S. 3548--Coronavirus Aid, Relief, and. Economic Security Act FY 2021 Hospital Inpatient PPS (IPPS) Proposed Rule CMS Proposed Rule, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements; Most Favored Nation (MFN) model interim final rule with comment period (IFC) Executive Order 13948, on Lowering Drug Prices by Putting America First; General issues related to patient access to rare disease therapies, Part B and Part D drugs; issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; value-based payment arrangements; efforts to improve coding and coverage for rare disease therapies; rare disease patient and provider impacts from MFN

LobbyistCovered position, as disclosed
KATIE JONES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 3548 (116th), H.R. 5741 (116th), H.R. 3 (116th)

Copyright/Patent/Trademark CPT

S.1416--Affordable Prescriptions for Patients Act, Discussion Draft on Section 101 reform of the Patent Act--Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform

LobbyistCovered position, as disclosed
KATIE JONES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1416 (116th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.